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ABSTRACT
Objective: There is an urgent need to identify risk factors for sporadic intracranial aneurysm (IA) devel-
opment and rupture. A genetic component has long been recognized, but firm conclusions have been
elusive given the generally small sample sizes and lack of replication. Genome-wide association studies
have overcome some limitations, but the number of robust genetic risk factors for IA remains uncertain.
Methods: We conducted a comprehensive systematic review and meta-analysis of all genetic
association studies (including genome-wide association studies) of sporadic IA, conducted ac-
cording to Strengthening the Reporting of Genetic Association Studies and Human Genome Epi-
demiology Network guidelines. We tested the robustness of associations using random-effects
and sensitivity analyses.
Results: Sixty-one studies including 32,887 IA cases and 83,683 controls were included. We
identified 19 single nucleotide polymorphisms associated with IA. The strongest associations,
robust to sensitivity analyses for statistical heterogeneity and ethnicity, were found for the fol-
lowing single nucleotide polymorphisms: on chromosome 9 within the cyclin-dependent kinase
inhibitor 2B antisense inhibitor gene (rs10757278: odds ratio [OR] 1.29; 95% confidence inter-
val [CI] 1.21–1.38; and rs1333040: OR 1.24; 95% CI 1.20–1.29), on chromosome 8 near the
SOX17 transcription regulator gene (rs9298506: OR 1.21; 95% CI 1.15–1.27; and
rs10958409: OR 1.19; 95%CI 1.13–1.26), and on chromosome 4 near the endothelin receptor
A gene (rs6841581: OR 1.22; 95% CI 1.14–1.31).
Conclusions: Our comprehensivemeta-analysis confirms a substantial genetic contribution to sporadic
IA, implicatingmultiple pathophysiologic pathways, mainly relating to vascular endothelial maintenance.
However, the limited data for IA compared with other complex diseases necessitates large-scale repli-
cation studies in a full spectrum of populations, with investigation of how genetic variants relate to phe-
notype (e.g., IA size, location, and rupture status). Neurology 2013;80:2154–2165
GLOSSARY
ACE 5 angiotensin-converting enzyme; ANRIL 5 antisense noncoding RNA in the INK4 locus; CI 5 confidence interval;
CGAS 5 candidate gene association study; EDNRA 5 endothelin receptor type A; GWAS 5 genome-wide association
studies; IA 5 intracranial aneurysm; IL 5 interleukin; LD 5 linkage disequilibrium; MMP 5 matrix metalloproteinase; OR 5
odds ratio; SAH 5 subarachnoid hemorrhage; SNP 5 single nucleotide polymorphism.
Intracranial aneurysms (IAs) are present in 2%–5% of the general population; approximately
0.7%–1.9% of cases rupture, causing subarachnoid hemorrhage (SAH).1 The annual incidence
of SAH is 8–9 in 100,000, yet because of the high risk of death or severe disability2 and younger
age at onset compared with other stroke types (40–65 years),3 SAH has a disproportionately
large socioeconomic impact.
SAH has been associated with commonmodifiable risk factors, including hypertension, smoking,
and alcohol intake.4–6 However, a genetic component has long been recognized; for example, first-
degree relatives of patients with aneurysmal SAH have a 4- to 7-fold increased risk of being affected
compared with the general population.7,8 Candidate gene association studies (CGAS) of sporadic IA
have identified numerous potential risk loci, but these studies have been limited by small sample
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sizes and lack of replication. More recently,
genome-wide association studies (GWAS) have
identified novel genetic loci strongly associated
with IAs,9–14 but these still explain only a frac-
tion of the genetic risk.
Thus, the number of true genetic risk factors
and the strength of their associations with IAs
remain uncertain. The pooling of data from
all genetic association studies allows risk esti-
mates to be determined with more precision
than is possible from any single study and
allows assessment of robustness to statistical
heterogeneity and population ethnicity differ-
ences across studies. We therefore undertook
a comprehensive systematic review and meta-
analysis of all published CGAS and GWAS of
sporadic IA, including sensitivity analyses for
statistical heterogeneity and ethnicity.
METHODS Our meta-analysis was conducted in accordance
with the Human Genome Epidemiology Network guidelines15
and followed published recommendations to improve the quality
of meta-analyses of genetic association studies.16 We assessed the
quality of reporting of genotyping on the basis of the Strength-
ening the Reporting of Genetic Association Studies statement.17
Search strategy. Electronic databases (PubMed, EMBASE, and
Google Scholar) were used to retrieve potentially relevant articles
on human genetic studies of IAs and SAH that had been published
up to December 2012. Search terms used under the Medical Subject
Headings were aneurysm(s), intracranial aneurysm(s), subarachnoid
hemorrhage, genetics, SNPs [single nucleotide polymorphisms], pol-
ymorphism, GWAS, and linkage and candidate gene(s).
Articles in all languages were searched (see figure 1 for a flow
diagram of the search strategy) and translated as necessary. After
relevant articles were retrieved, references were also checked for
other potentially relevant articles not found in the initial search.
Selection criteria. We included cohort or case-control studies
evaluating associations of genetic polymorphisms with proven
IA (using CT/MR angiograms or digital subtraction angiogra-
phy), including unrelated individuals from CGAS and GWAS,
in all ethnicities. Where duplicate datasets or cohorts existed, only
the largest study was included. All single nucleotide polymor-
phisms (SNPs) evaluated in at least 2 published studies (CGAS
or GWAS) were included in meta-analysis. Exclusion criteria
were a history of inherited conditions associated with IAs, e.g.,
adult polycystic kidney disease or Ehlers-Danlos syndrome.
Data extraction. Data were extracted by 2 of the authors (V.S.A.
and D.J.W.), and differences were resolved by consensus. Where
available, genotype frequencies for each SNP were recorded.
Where they were unavailable, we estimated the number of cases
per genotype category by using published information on risk
allele frequencies and odds ratios (ORs) for IA.
Statistical analysis. For each genetic polymorphism with more
than one publication, meta-analysis was performed to determine a
pooledOR and 95% confidence intervals (CIs) by using a fixed-effect
model (Mantel-Haenszel method). Interstudy heterogeneity p values
were measured fromCochran Q test and quantified by using Higgins
I2 statistic. SNP associations showing significant interstudy heteroge-
neity (interstudy heterogeneity p values ,0.05 and I2 .50%) were
examined under a random-effects (DerSimonian and Laird) model,
and, where appropriate, subjected to sensitivity analysis to determine
the effect of individual studies on the pooled OR. Ethnic subgroup
analysis was also performed where appropriate.
All genetic models (dominant, recessive, and additive) were as-
sessed in studies recording genotype frequencies. Bonferroni correc-
tion was applied for multiple testing (p , 0.01). In studies not
recording genotype frequencies, per-allele (additive) ORs were
pooled with calculation of CIs. Controls were checked to be in
Hardy-Weinberg equilibrium for each study before meta-analysis.
Publication bias was assessed by using the Egger regression
asymmetry test and visualization of funnel plots. Review Manager
(RevMan) version 5.2 from the Cochrane Collaboration (London,
UK), 2011, and Comprehensive Meta-Analysis (2.2) from Biostat
(Tampa, FL) were used to create the forest plots and perform sen-
sitivity and publication bias analysis.
RESULTS Our search identified 642 articles, of which
134 articles met initial inclusion criteria. Two studies
published in Chinese were translated. After screening
for duplication and eligibility, data from 66 case-control
studies (60 CGAS and 6 GWAS) were included.
Figure 1 Flow chart illustrates the number of studies evaluated in this meta-
analysis
GWAS 5 genome-wide association studies; IA 5 intracranial aneurysm; SNP 5 single nucle-
otide polymorphism.
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Genotype and allele frequencies were reported in 48
publications; the remaining 18 reported additive ORs.
In total, 32,887 cases and 83,683 control subjects were
included, evaluating 41 polymorphisms in 29 genes (fig-
ure 1). The studies encompassed mainly white Euro-
pean, Chinese, and Japanese populations. Risk allele
frequencies and control Hardy-Weinberg equilibrium
status for each study of all SNPs meta-analyzed are
shown in table e-1 on the Neurology® Web site at
www.neurology.org.
We identified 19 SNPs (from CGAS and GWAS)
that were significantly associated with IAs in at least
one genetic model (table 1). The most robust associa-
tions were seen in 11 of 12 SNPs discovered from
GWAS (table 1), with the strongest associations for
loci on chromosome 9 (rs1333040 and rs10757278),
chromosome 8 (rs9298506 and rs10958409), and
chromosome 4 (rs6841581; figure 2). Other GWAS
loci variants associated with IAs included 9p21.3
(rs2891168), 2q33 (rs1429412 and rs700651), 7q13
(rs4628172), 12q22 (rs6538595), and 20p20.1
(rs1132274; table 1 and figures e-1 and e-2).
Eight SNPs from CGAS were significantly associ-
ated with IAs; SERPINA3 (rs4934) and 2 variants relat-
ing to collagen genes (COL1A2 [rs42524 G.C] and
COL3A1 [rs1800255 G.A]) showed the most robust
associations. The remaining significantly associated
CGAS SNPs included heparan sulfate proteoglycan 2
(rs3767137), versican (rs251124 and rs173686), angi-
otensin-converting enzyme (ACE) I/D, and interleukin
6 (IL6) G572C (table 1, figure 3, and figure e-2).
SNPs demonstrating statistical heterogeneity. Nine of
the 19 significantly associated SNPs (SERPINA3,
ACE I/D, IL6 G572C, chondroitin sulfate proteogly-
can 2 [rs173686, rs1333040, rs700651, rs9298506,
rs10958409, and rs4628172]) showed significant sta-
tistical heterogeneity; random-effects and sensitivity
analyses were possible only for the 7 variants reported
in more than 2 publications (table 2). After sensitivity
analysis, the SERPINA3, ACE I/D, and IL6 G572C
SNPs (figure 3F) derived from CGAS no longer
showed an association with IA.
Ethnicity analysis. Nine SNPs (2 from CGAS and 7
from GWAS) were subjected to subgroup analysis to
determine the effect of ethnicity (table 3 and figures
e-3 to e-6). Associations with IA in Japanese, Chinese,
and white populations were compared for each SNP,
after which 5 of these 9 SNPs (all from GWAS) re-
mained robustly associated with IA in all groups (table 3).
Publication bias. Inspection of funnel plots and calcula-
tion of Egger p values confirmed that none of the SNPs
(CGAS or GWAS) associated with IAs (table 1) showed
publication bias. See figures e-7 to e-11 for funnel plots
of all SNPs (CGAS and GWAS) associated with IA.
CGAS not confirming associations with IAs. Twenty-two
candidate SNPs reported in more than one study were
not associated with IAs after meta-analysis (table e-2),
including the following: endothelial nitric oxide syn-
thase variable number tandem repeat 4a/4b, endo-
thelial nitric oxide synthase T786C, endothelial
nitric oxide synthase G894T, endoglin intron
7 Wt/Ins, matrix metalloproteinase (MMP)-3 5A/
6A, elastin intron 20T.C, elastin intron 23C.T,
IL-1b C5111T, IL-6 G174C, plasminogin activator
inhibitor-1 4G/5G, glycoprotein IIIa A1/A2, factor
XIII valine/leucine, APOE e2 and e4, COL4A1 C.T
(rs3783107), fibrillin-2 C.G (rs331079), MMP-2
C.T (rs243865), MMP-9 C1562T (rs3918242),
COL3A1 (rs2138533C.T and rs11887092A.G),
rs10757272C.T, and rs11661542A.C.
DISCUSSION This comprehensive systematic review
and meta-analysis has identified 19 SNPs associated
with IAs among 32,887 cases and 83,683 controls.
The variety of genes implicated by these SNPs sug-
gests that multiple pathophysiologic pathways,
mainly involved in vascular endothelial maintenance
and extracellular matrix integrity, are likely to con-
tribute to IA development and rupture. The most
robust SNPs identified arose from variants on chro-
mosomes 4, 8, and 9, derived from GWAS and con-
firmed by subsequent replication case-control studies.
Genetic variants associated with IAs identified by GWAS.
SNPs with potential roles in vascular endothelial mainte-
nance. The SNP rs1333040 located on chromosome
9p21.3 in the cyclin-dependent kinase inhibitor 2B
antisense gene was strongly associated with IAs. Two
major linkage disequilibrium (LD) blocks exist within
the 9p21.3 locus: one associated with vascular diseases
and the other associated with diabetes. This locus is
associated with a wide spectrum of arterial disorders,
including coronary artery disease and abdominal aortic
aneurysms,18 raising the possibility that there are as yet
unidentified common processes involved in all these
common cardiovascular pathologies. The cyclin-
dependent kinase inhibitor 2B antisense gene, on
intron 12, is associated with cell cycle signaling,
although its exact biological roles are not fully under-
stood.9,10 Association of the rs1333040 SNP with IAs
was found to be independent of smoking and hyper-
tension in one study.19 In multivariable analysis, this
SNP was preferentially associated with posterior com-
municating artery aneurysms, providing preliminary
evidence that aneurysm site could be related to genetic
factors.19 However, larger cohorts will need to be stud-
ied in addition to scanning the entire region to check
which SNPs are in LD with the rs1333040-T allele
and whether they have any cumulative (epistatic) effect
on IA phenotype, including location.
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Table 1 SNPs associated with IAs
Gene/locus SNP
Genetic
model No. studies Cases Controls FE OR (95% CI)
pcorrected
(Bonferroni) pHet (I2)
Robust association
after random
effects/sensitivity
analyses
Potential biological
mechanism of
association with IA
Genome-wide association study SNP associations
9p21.3 C.T (rs1333040) Additive 129–11,13,14,19,24 11,949 29,014 1.24 (1.2–1.29) 9.83 3 10208 5.40 3 10208 (80%) ✓ Vascular endothelium
9p21 A.G (rs10757278) Additive 718–21,24 3,394 17,075 1.29 (1.21–1.38) 1.59 3 10213 0.84 (0%) NA Vascular endothelium
8q11 A.G (rs9298506) Additive 89,10,13,24 9,246 26,331 1.21 (1.15–1.27) 1.55 3 10213 1.90 3 10207 (84%) ✓ Vascular endothelium
8q11 A.G (rs10958409) Additive 89–11,13,20,24 9,873 27,029 1.20 (1.15–1.26) 1.78 3 10215 6.87 3 10205 (76%) ✓ Vascular endothelium
4q31.23 A.G (rs6841581) Additive 612 4,370 14,181 1.22 (1.14–1.31) 1.95 3 1028 0.39 (4%) NA Vascular endothelium
9p21.3 C.G (rs2891168) Additive 214,19 2,076 1,985 1.32 (1.21–1.44) 9.84 3 10210 0.98 (0%) NA Vascular endothelium
2q33 G.A (rs1429412) Additive 49,11,24 2,675 7,632 1.20 (1.12–1.30) 1.07 3 10206 0.30 (18%) NA Unknown
2q33 G.A (rs700651) Additive 69,13,20,24 4,283 13,236 1.11 (1.06–1.18) 7.13 3 10205 1.17 3 10202 (66%) ✓ Unknown
7q13 G.T (rs4628172) Additive 211,13 2,443 6,376 1.11 (1.03–1.19) 4.04 3 10203 4.71 3 10203 (87%) NA Unknown
12q22 G.A (rs6538595) Additive 612 4,370 14,181 1.16 (1.10–1.23) 1.12 3 1027 0.98 (0%) NA Unknown
20p12.1 G.A (rs1132274) Additive 512 4,370 14,181 1.19 (1.11–1.28) 8.29 3 1027 0.52 (0%) NA Unknown
Candidate gene SNP associations
SERPINA3 A.G (rs4934) Dominant 340–42 892 1,029 2.22 (1.68–2.94) ,0.00001 ,0.00001 (97%) 3 Extracellular matrix
Recessive 0.80 (0.49–1.31) 0.25 0.04 (69%)
Additive 1.27 (1.07–1.50) 0.0002 ,0.00001 (94%)
COL1A2 G.C (rs42524) Dominant 343–45 812 806 1.77 (1.14–2.75) 0.0009 0.09 (58%) NA Extracellular matrix
Recessive 1.14 (0.16–7.94) 0.86 0.31 (4%)
Additive 1.69 (1.11–2.57) 0.001 0.06 (64%)
COL3A1 G.A (rs1800255) Dominant 246,47 546 2,235 1.55 (1.21–2.00) ,0.00001 0.25 (23%) NA Extracellular matrix
Recessive 1.31 (0.72–2.38) 0.25 0.70 (0%)
Additive 1.40 (1.14–1.72) ,0.0001 0.26 (21%)
HSPG2 A.G (rs3767137) Additive 231,32 1,316 1,742 1.22 (1.08–1.39) 0.002 0.122 (58%) NA Extracellular matrix
Versican (CSPG2) C.T (rs251124) Additive 330–32 1,489 1,687 1.25 (1.1–1.41) 0.0007 0.201 (38%) NA Extracellular matrix
Versican (CSPG2) A.G (rs173686) Additive 230,31 857 879 1.23 (1.05–1.43) 0.008 0.013 (84%) NA Extracellular matrix
ACE I/D Dominant 548252 767 1,172 0.82 (0.61–1.12) 0.66 0.002 (76%) 3 Vascular endothelium
Recessive 1.39 (1.05–1.84) 0.002 0.01 (69%)
Additive 1.23 (1.07–1.40) 0.003 0.47 (0%)
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The SNP rs10757278 on chromosome 9p21.3,
located in a noncoding RNA region called ANRIL
(antisense noncoding RNA in the INK4 locus),
showed robust association with IAs, but its function
remains unclear. Moreover, the observed association of
rs10757278 with IA may arise frommoderate LDwith
the known IA risk variant rs1333040 SNP (r5 0.59),
from which it is approximately 41 kbp upstream.20
However, these 2 SNPs were not in strong LD in a
Japanese population, raising the possibility of a smaller
LD block associated with IA. In a Japanese study,19
haplotype analysis of both risk alleles of these SNPs
demonstrated significant association with IAs (OR
1.56; 95% CI 1.32–1.85; p 5 2.9 3 10207). Func-
tional studies show altered ANRIL expression as a
result of variations within the 9p21.3 region,14 with
reduced expression of RNA encoded by CDKN2A
and CDKN2B in mice14; these 2 genes, adjacent to
the 9p21 region, encode tumor-suppressor proteins
(p14–16), which are involved in cell proliferation.21
Moreover, p14 levels correlate with ANRIL activity
and modulate MMP-3 levels, which may influence
extracellular matrix repair.21
In the most recent GWAS14 in a Caucasian popu-
lation of familial and sporadic IA, 6 SNPs, also located
in the 9p21.3 region, were associated with IA; one of
these (rs6475606) achieved GWAS-level statistical sig-
nificance (OR 1.34; p5 4.293 10207) for association
with sporadic and familial IAs. Association with the
rs1333040 SNP was also confirmed in this study,14
further strengthening association of this locus with IA.
Two SNPs on chromosome 8q (rs10958409 and
rs9298506), surrounding the SOX17 gene, were studied
in European and Japanese populations; rs10958409 was
associated in both populations, but the rs9298506 SNP
was associated with IA in the European but not Japanese
population. SOX17 plays an important role in generation
and maintenance of stem cells of endothelial and hema-
topoietic lineages, crucial in the formation and mainte-
nance of vascular endothelium.22,23 Furthermore, SOX17
knockout mice show multiple vascular abnormalities
reflecting defective endothelial remodeling.22 Defective
stem cells involved in vascular maintenance are thus
plausible targets in IA pathogenesis. The heterogene-
ity observed in the meta-analysis of these 2 SNPs
may partly be explained by the difference in risk allele
frequencies in the white population (table e-1)24
compared with the other populations studied
(rs10958409, risk allele frequency 0.88 vs approxi-
mately 0.2; rs9298506, risk allele frequency 0.17 vs
approximately 0.80). Further support implicating
chromosome 8 loci was shown in a recent GWAS,14
in which a novel SNP, also in the region of the
SOX17 gene, was significantly associated with IAs
(rs1072737: OR 1.22; 95% CI 1.07–1.39), inde-
pendent of smoking. For both SOX17 loci, in the
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Figure 2 Forest plots (additive model) for genome-wide association studies in all populations
(A) rs1333040 single nucleotide polymorphism (SNP); (B) rs10757278 SNP; (C) rs9298506; (D) rs10958409; (E)
rs6841581. CI 5 confidence interval; IA 5 intracranial aneurysm.
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Figure 3 Forest plots for candidate gene single nucleotide polymorphisms associated with intracranial aneurysms
(A) Dominant model forest plots for SERPINA3 single nucleotide polymorphism (SNP). (B) COL3A1 (rs1800255) dominant model forest plot. (C) COL1A2
(rs42524) dominant model forest plot. (D)ACE I/D recessive model forest plot. (E) IL6G572C SNP recessive model forest plot before sensitivity analysis. (F)
IL6 G572C SNP recessive model forest plot after sensitivity analysis. CI 5 confidence interval; IA 5 intracranial aneurysm; M-H 5 Mantel-Haenszel.
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most recent GWAS,14 smoking was an independent
risk factor, acting in a multiplicative manner (chromo-
some 8: rs1072737; OR 2.12; 95% CI 1.76–2.56 and
chromosome 9: rs6475606; OR 2.11; 95% CI 1.77–
2.52).
A further recent GWAS12 found the SNP
rs6841581A.G on chromosome 4q31.23, coding for
the endothelin receptor type A (EDNRA) gene, was
significantly associated with IA in Dutch, Finnish, and
Japanese populations (OR 1.22; 95% CI 1.14–1.31;
Table 2 Random-effects and sensitivity analyses of associated SNPs that showed significant statistical
heterogeneity under fixed-effects modeling
SNP
No.
studies
Studies
excluded
FE OR (95% CI)
before adjustment
Random-effects
OR (95% CI)
FE OR (95% CI) after
sensitivity analysis Genetic model
SERPINA3 3 Liu42 2.22 (1.68–2.94)a 2.12 (0.36–12.31) 1.07 (0.74–1.53) Dominant
1.27 (1.07–1.50)a 1.25 (0.61–2.59) 0.97 (0.79–1.19) Additive
ACE I/D 5 Slowik50 1.39 (1.05–1.84)a 1.44 (0.86–2.42) 1.20 (0.88–1.62) Recessive
IL6 G572C 5 Sun36 0.47 (0.34–0.65)a 1.49 (0.24–9.27) 1.03 (0.65–1.62) Recessive
0.61 (0.49–0.75)a 0.95 (0.31–2.85) 1.04 (0.79–1.39) Additive
rs1333040 11 Low13 1.23 (1.19–1.28)a 1.26 (1.15–1.39)a 1.31 (1.26–1.37)a Additive
rs700651 6 Low13 1.11 (1.06–1.18)a 1.14 (1.03–1.25)a 1.19 (1.11–1.28)a Additive
rs9298506 8 Low13 1.21 (1.15–1.27)a 1.24 (1.08–1.41)a 1.32 (1.24–1.39)a Additive
rs10958409 9 410,11,20,24b 1.20 (1.15–1.26)a 1.22 (1.1–1.34)a 1.23 (1.17–1.3)a Additive
Abbreviations: ACE 5 angiotensin-converting enzyme; CI 5 confidence interval; FE 5 fixed-effects model; IL 5 interleukin;
OR 5 odds ratio; SNP 5 single nucleotide polymorphism.
aSignificant association with IA.
b Four studies, including one white population and 3 Japanese populations, were excluded.
Table 3 Subgroup ethnicity analysis
SNP
No.
studies Ethnicity
FE OR, all ethnicities
(all studies)
FE OR (95% CI),
ethnicity subanalysis pcorrected pHet (I2) Genetic model
ACE I/D 4/5 White 1.39 (1.05–1.84) 1.42 (1.06–1.92)a 0.002 0.006 (76%) Recessive
Japanese 1.20 (0.56–2.57) 0.54 NA Recessive
IL6 G572C 3/5 Chinese 0.30 (0.19–0.47) 0.41 (0.29–0.58)a ,0.00001 0.0001 (95%) Recessive
2/5 White 4.26 (0.92–19.7) 0.1 0.03 (78%) Recessive
3/5 Chinese 0.58 (0.44–0.75) 0.50 (0.39–0.64)a ,0.00001 ,0.00001 (97%) Additive
2/5 White 1.38 (0.83–2.29) 0.1 0.19 (42%) Additive
rs1333040 6/11 Japanese 1.24 (1.2–1.29) 1.15 (1.09–1.22)a 1.75 3 10206 3.06 3 10208 (88%) Additive
5/11 White 1.30 (1.24–1.36)a 1.91 3 10206 0.78 (0%) Additive
rs10757278 5/7 White 1.29 (1.21–1.38) 1.30 (1.2–1.43)a 1.2 3 10209 0.91 (0%) Additive
2/7 Japanese 1.27 (1.13–1.41)a 2.6 3 10205 0.22 (33%) Additive
rs9298506 5/8 White 1.21 (1.15–1.27) 1.35 (1.27–1.44)a 2.4 3 10204 0.52 (0%) Additive
3/8 Japanese 1.03 (0.95–1.12) 0.45 6.54 3 10204 (86%) Additive
rs10958409 5/9 White 1.2 (1.15–1.26) 1.31 (1.23–1.39)a 8.2 3 10202 0.052 (62%) Additive
4/9 Japanese 1.09 (1.02–1.17)a 0.009 0.08 (55%) Additive
rs700651 3/3 White 1.11 (1.06–1.18) 1.19 (1.09–1.29)a 4.82 3 10205 0.23 (31%) Additive
3/3 Japanese 1.06 (0.94–1.31) 0.08 0.02 (75%) Additive
rs6841581 4/6 White 1.22 (1.14–1.31) 1.25 (1.13–1.38)a 1.21 3 10205 0.18 (38%) Additive
2/6 Japanese 1.2 (1.08–1.32)a 3.56 3 10204 0.87 (0%) Additive
rs6538595 4/6 White 1.16 (1.10–1.23) 1.16 (1.08–1.24)a 2.13 3 10205 0.91 (0%) Additive
2/6 Japanese 1.17 (1.06–1.28)a 1.49 3 10203 0.6 (0%) Additive
Abbreviations: ACE 5 angiotensin-converting enzyme; CI 5 confidence interval; FE 5 fixed-effects model; I2 5 Higgins statistic demonstrating degree of
interstudy heterogeneity; IA5 intracranial aneurysm; IL5 interleukin; NA5 not applicable; OR 5 odds ratio; pHet 5 interstudy heterogeneity p value; SNP 5
single nucleotide polymorphism.
a Significant association with IA.
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p 5 1.95 3 1028). Another GWAS13 in a Japanese
population showed that the rs6842241 SNP, located at
4q31.22 near the EDNRA gene, was significantly asso-
ciated with IA (OR 1.25; 95% CI 1.16–1.34; p 5
9.583 10209). EDNRA is a G-protein–coupled recep-
tor for endothelins, which modulate vasoconstriction
and vasodilatation after hemodynamic insult. Endo-
thelin-1—the predominant isoform in vascular
smooth-muscle cells—activates EDNRA. Endothelin
signaling is activated at the site of vascular injury,12,25
causing cell proliferation; indeed, after SAH, EDNRA
and endothelin-1 protein levels are both increased in
CSF.26–28 Alternatively, downregulation of EDNRA
signaling could lead to defective vascular repair, allowing
aneurysms to develop after injury, a hypothesis sup-
ported by functional analysis of EDNRA variants show-
ing lower transcriptional activity for the rs6841581
risk allele (G).13
SNPs with unknown function or not examined in more
than 2 studies. Five SNPs from GWAS do not corre-
spond to genes with any known functions relevant to
IA development. Two of these SNPs (rs1429412 and
rs700651), at locus 2q33, flank the BOLL gene
(involved in germ cell development) and the phospho-
lipase C–like 1 gene (involved in intracellular cascade
reactions with abolished phospholipase C activity).
Phospholipase C–like 1 lies close to the vascular endo-
thelial growth factor receptor-2, which is involved in
CNS angiogenesis and is a marker for endothelial pro-
genitor cells. Three further SNPs on chromosome 2
were associated with familial IAs: rs11693075 (close to
the histone deacetylase complex SAP130 gene),
rs1897472, and rs3769801 (both located within the
phosphodiesterase-1 gene).14
One associated SNP located on chromosome 7
(rs4628172 G.T) is within the TMEM195 gene,
which encodes transmembrane proteins, possibly
involved in fatty acid biosynthesis and iron bind-
ing.11,13 Further associated SNPs from the latest
GWAS include variants on chromosome 12q22
(rs6538595, rs11112585, and rs2374513) within the
C12orf75 gene.14 The rs1132274 G.T SNP on chro-
mosome 20p12.1 was also associated with IA.10 How-
ever, none of these SNPs yet has known clear
functional relevance to IA.
Three further loci not included in this meta-analysis
(because they were reported in only one study) showed
significant association with IAs.10 These loci included
18q11.2 (rs11661542), 10q24.32 (rs12413409), and
13q13.2 (rs9315204), but their mechanisms of associ-
ation remain unclear.
Genetic variants associated with IAs identified by CGAS.
Eight SNPs from CGAS were associated with IAs in
our meta-analysis, albeit with significant statistical
heterogeneity. These SNPs relate to genes with
plausible relevance to IA biology, including those impor-
tant for extracellular matrix integrity, inflammatorymedi-
ators, and vascular endothelium maintenance.
Extracellular matrix gene variants may predispose to IA
development by weakening arterial walls. In our meta-
analysis, 6 such SNPs showed significant associations
with IA: COL1A2 (rs42524), COL3A1 (rs1800255),
SERPINA3, versican (rs251124 and rs173686), and hep-
aran sulfate proteoglycan 2 (rs3767137). The COL1A2
rs42524 SNP is located on chromosome 7q22.1 close to
the elastin gene—a protein component of arterial walls,
previously associated with IAs in a linkage-association
study.29 Collagen type 1 is usually found in the adventi-
tial layer of cerebral arteries and provides tensile strength,
making it a plausible factor in IA development. Never-
theless, caution is needed in generalizing this result as all
3 studies identified were in Far East populations; for
robust association to be confirmed, this SNP has to be
examined in other populations, including Europe,
because risk allele frequencies may differ. Collagen type
3 (COL 3A1) was investigated in 3 Chinese populations;
rs1800255 (G.A) was the only SNP significantly asso-
ciated with IA, but replication in other ethnicities and
larger cohorts is required to confirm these findings.
We also found associations between 2 versican
genetic variants (rs251124 and rs173686) and IAs
in Dutch, Japanese, and Chinese populations.30–32
In a previous linkage study on a Japanese cohort,
chromosome 5q14.3, very close to the versican gene,
was implicated in IA.30 In vivo studies on abdominal
aortic aneurysm samples found reduced versican mes-
senger RNA expression,33,34 which could reflect a
decline in smooth-muscle cells associated with weak-
ness in the vascular wall. Moreover, a GWAS35 on
thoracic and aortic dissections showed significant
association with the 5q13–14 locus, corresponding
to the versican gene.
The proinflammatory cytokine IL6 G572C SNP
had an overall protective association with IAs in a
recessive model. However, there was significant sta-
tistical heterogeneity, and sensitivity analysis revealed
no association once one Chinese study36 was
excluded, which may partly reflect the greater risk
allele frequency (0.79 vs 0.05–0.09) and inclusion
of only unruptured IAs in this study.36 Another
source of heterogeneity may be sex, because one other
study37 included only male controls, and this may not
be appropriate because SAH has a female predomi-
nance. Therefore, the overall association of this SNP
with IA is not robust. Sustained abnormal vascular
remodeling in association with inflammation is
hypothesized to be a key mechanism in IA develop-
ment.22 IL-6 can injure vessel walls by inhibiting col-
lagen synthesis, thus increasing wall fragility and
increasing the risk of aneurysmal dilatation. IL-6 lev-
els are increased in the CSF and plasma after
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SAH,38,39 but whether this is directly related to the
G572C SNP remains uncertain because in these stud-
ies patients were not genotyped for the mutant allele;
moreover, IL-6 may be released as part of a systemic
inflammatory response in the acute phase after SAH.
Strengths of our study. Our systematic review and
meta-analysis is the largest and most comprehensive
to date on genetic variants associated with IAs. We as-
sessed strength of association by using multiple
genetic models and carefully assessed the robustness
of all associations by performing random-effects, sen-
sitivity, and ethnic subgroup analyses. We conducted
our analysis and reporting according to quality guide-
lines for genetic association studies, including Human
Genome Epidemiology Network15 and Strengthening
the Reporting of Genetic Association Studies.17
Limitations of our study. Our assessment of interstudy
heterogeneity by visual inspection of the forest plots
and sensitivity analyses only partly addresses potential
sources of heterogeneity between studies. Further
individual patient data are required on other factors
that could also contribute to heterogeneity, such as
sex proportions, age, genotyping methods or errors,
disease phenotype (aneurysm size, location, and rup-
ture status), and environmental risk factor status. Our
meta-analysis was only able to pool reported posi-
tively associated SNPs from the 6 GWAS studies,
but data on many SNPs sequenced not reaching the
threshold for GWAS statistical significance were not
available, thus limiting our meta-analysis to 41 SNPs
in total. Indeed, for many of the candidate-gene stud-
ies, pooling all available data from GWAS might
allow more robust risk estimates to be calculated;
despite 8 candidate gene SNPs being associated with
IAs, on average only 2.7 publications were available
for each variant.
We have identified 19 candidate SNPs associated
with IAs, of which 16 were robust to random-effects
or sensitivity analyses. The ORs suggest that the
genetic contribution to aneurysm development is
substantial, but the variants identified implicate mul-
tiple pathophysiologic mechanisms, particularly
involving vascular endothelium maintenance. Never-
theless, the amount of data on genetic associations
with IAs remains much smaller than for other com-
plex diseases, so further large replication studies in a
full spectrum of populations are required, ideally
using GWAS or exome sequencing to identify rarer
functional variants. A limitation of most studies
included is that both ruptured and unruptured IAs
were analyzed together; because only a minority of
IAs are destined to rupture, future studies should
address genetic risk factors specifically related to rup-
ture status. Another important area for future research
is to explore how genetic factors are related to
aneurysm location, size, or morphology, because
there may be specific genetic associations for particu-
lar aneurysm phenotypes (which may also relate to
rupture risk). Finally, validation studies of risk models
in prospective cohorts (e.g., of unruptured IAs fol-
lowed up for rupture risk) would be helpful in deter-
mining the relevance of genetic risk loci in addition to
well-established risk factors for overall disease pheno-
type, to ultimately reduce the devastating burden of
aneurysmal SAH.
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